Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

This is a correction to:
Bruce E Sands, Geert D’Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass, Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study, Inflammatory Bowel Diseases, 2024; izae024, https://doi.org/10.1093/ibd/izae024

In the originally published version of this manuscript, there was an error in the results section of the abstract. The bolded numbers should be swapped in the following sentence:

From:
Among W52 mirikizumab responders, clinical response at W104 was 74.5%, 87.2%, and 96.7% and clinical remission was 76.6%, 89.0%, and 98.3% for NRI, mNRI, and OC, respectively. Among W52 mirikizumab remitters, clinical response at W104 was 54.0%, 62.8%, and 70.1% and clinical remission was 65.6%, 76.1%, and 84.2%.

To:
Among W52 mirikizumab responders, clinical response at W104 was 74.5%, 87.2%, and 96.7% and clinical remission was 54.0%, 62.8%, and 70.1% for NRI, mNRI, and OC, respectively. Among W52 mirikizumab remitters, clinical response at W104 was 76.6%, 89.0%, and 98.3% and clinical remission was 65.6%, 76.1%, and 84.2%.

Additionally,
The “N” values for Supplemental Figure 2, Panel B, was incorrect. The values should be as following:
Original: N=156 N=156 N=156 N=119 N=119 N=119
Corrected: N=239 N=239 N=211 N=154 N=154 N=136
These errors have been corrected.
The modified intent-to-treat population was used with NRI, mNRI, and OC methods used for missing data. Responders: ≥30% and 2-point decrease from baseline in the composite clinical endpoint of the sum of ES, SF, and RB subscores, and RB=0 or 1, or ≥1-point decrease from baseline. Remitters: MM5 SF=0 or SF=1 with ≥1-point decrease from baseline; RB=0; ES=0 or 1. Alternate clinical remission: SF=0 or SF=1; RB=0; and ES=0 or 1 (excluding friability). Endoscopic remission: ES=0 or 1 (excluding friability). Abbreviations: CI=confidence interval; ES=endoscopic subscore; MMS= modified Mayo score; mNRI=modified NRI; NRI=nonresponder imputation; OC=observed case; RB=rectal bleeding; SF=stool frequency. For the mNRI population: For W52 responders for endpoints, n (%): Treatment discontinuation = 23 (9.6) and sporadic missing = 32 (13.4) for alternate clinical remission; treatment discontinuation = 23 (9.6) and sporadic missing = 5 (2.1) for endoscopic remission. For W52 remitters, n (%): Treatment discontinuation = 14 (9.1) and sporadic missing = 20 (13.0) for alternate clinical remission; treatment discontinuation = 14 (9.1) and 4 (2.6%) for endoscopic remission.